Ubs Asset Management Americas Inc Entrada Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 14,156 shares of TRDA stock, worth $248,579. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,156
Previous 10,512
34.67%
Holding current value
$248,579
Previous $149,000
51.68%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TRDA
# of Institutions
101Shares Held
28.1MCall Options Held
34.5KPut Options Held
16.4K-
Baker Bros. Advisors LP New York, NY4.87MShares$85.4 Million0.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$77.7 Million48.7% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$77.4 Million28.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.05MShares$53.6 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.71MShares$30.1 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $551M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...